Lazard Asset Management’s Boston Scientific BSX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $306M | Buy |
4,880,504
+970,473
| +25% | +$77.6M | 0.5% | 47 |
|
|
2025
Q4 | $373M | Sell |
3,910,031
-2,809,738
| -42% | -$275M | 0.63% | 32 |
|
|
2025
Q3 | $656M | Buy |
6,719,769
+87,009
| +1% | +$9.01M | 0.88% | 22 |
|
|
2025
Q2 | $712M | Buy |
6,632,760
+372,200
| +6% | +$37.7M | 0.98% | 16 |
|
|
2025
Q1 | $632M | Sell |
6,260,560
-217,673
| -3% | -$21.9M | 0.97% | 21 |
|
|
2024
Q4 | $579M | Sell |
6,478,233
-775,800
| -11% | -$68.3M | 0.85% | 28 |
|
|
2024
Q3 | $608M | Sell |
7,254,033
-259,481
| -3% | -$20.5M | 0.81% | 35 |
|
|
2024
Q2 | $579M | Buy |
7,513,514
+83,675
| +1% | +$6.12M | 0.73% | 40 |
|
|
2024
Q1 | $509M | Sell |
7,429,839
-1,398,409
| -16% | -$89.9M | 0.62% | 43 |
|
|
2023
Q4 | $510M | Sell |
8,828,248
-78,889
| -0.9% | -$4.21M | 0.65% | 41 |
|
|
2023
Q3 | $470M | Sell |
8,907,137
-285,441
| -3% | -$15M | 0.64% | 39 |
|
|
2023
Q2 | $497M | Sell |
9,192,578
-2,226,793
| -20% | -$116M | 0.61% | 44 |
|
|
2023
Q1 | $571M | Sell |
11,419,371
-1,286,098
| -10% | -$60.6M | 0.75% | 32 |
|
|
2022
Q4 | $588M | Buy |
12,705,469
+165,750
| +1% | +$7.18M | 0.81% | 27 |
|
|
2022
Q3 | $486M | Sell |
12,539,719
-113,333
| -0.9% | -$4.55M | 0.71% | 34 |
|
|
2022
Q2 | $472M | Buy |
12,653,052
+2,416,974
| +24% | +$98.4M | 0.64% | 39 |
|
|
2022
Q1 | $453M | Buy |
10,236,078
+336,929
| +3% | +$14.6M | 0.53% | 44 |
|
|
2021
Q4 | $421M | Buy |
9,899,149
+176,763
| +2% | +$7.43M | 0.45% | 55 |
|
|
2021
Q3 | $422M | Buy |
9,722,386
+14,004
| +0.1% | +$620K | 0.48% | 51 |
|
|
2021
Q2 | $415M | Sell |
9,708,382
-123,618
| -1% | -$5.2M | 0.47% | 51 |
|
|
2021
Q1 | $380M | Buy |
9,832,000
+276,703
| +3% | +$10.5M | 0.46% | 50 |
|
|
2020
Q4 | $344M | Buy |
9,555,297
+919,471
| +11% | +$33.1M | 0.43% | 57 |
|
|
2020
Q3 | $330M | Buy |
8,635,826
+2,856,714
| +49% | +$110M | 0.46% | 56 |
|
|
2020
Q2 | $203M | Buy |
5,779,112
+4,147,408
| +254% | +$149M | 0.31% | 75 |
|
|
2020
Q1 | $53.2M | Sell |
1,631,704
-96,373
| -6% | -$3.76M | 0.1% | 161 |
|
|
2019
Q4 | $78.1M | Sell |
1,728,077
-168,682
| -9% | -$7.06M | 0.11% | 149 |
|
|
2019
Q3 | $77.2M | Sell |
1,896,759
-29,955
| -2% | -$1.27M | 0.13% | 140 |
|
|
2019
Q2 | $82.8M | Buy |
1,926,714
+726,934
| +61% | +$28M | 0.13% | 131 |
|
|
2019
Q1 | $46M | Sell |
1,199,780
-90,416
| -7% | -$3.45M | 0.08% | 181 |
|
|
2018
Q4 | $45.6M | Buy |
1,290,196
+1,146,523
| +798% | +$41.6M | 0.08% | 164 |
|
|
2018
Q3 | $5.53M | Sell |
143,673
-18,948
| -12% | -$662K | 0.01% | 556 |
|
|
2018
Q2 | $5.32M | Buy |
+162,621
| New | +$4.9M | 0.01% | 552 |
|
Other funds holding BSX
VCM
VPM
Lazard Asset Management's BSX Position: Q1 2026 in Review
Lazard Asset Management increased its Boston Scientific (BSX) stake by 25% in Q1 2026, buying an estimated $77.6M and bringing the position to 4,880,504 shares worth $306M. The position accounts for 0.5% of the portfolio, ranked #47.
Lazard Asset Management first reported a position in BSX in Q2 2018 and has held it in 32 quarters since. The position peaked at $712M in Q2 2025. 1,664 funds tracked by Wall St. Rank hold BSX as of Q1 2026.
- Lazard Asset Management held 4,880,504 shares of Boston Scientific worth $306M as of Q1 2026.
- Lazard Asset Management bought 970,473 Boston Scientific shares in Q1 2026, an estimated $77.6M.
- Boston Scientific made up 0.5% of Lazard Asset Management's portfolio in Q1 2026, its #47 holding.
- Lazard Asset Management first reported a position in Boston Scientific in Q2 2018 and has held it in 32 quarters since.
- Lazard Asset Management's Boston Scientific position peaked at $712M in Q2 2025.
- 1,664 funds tracked by Wall St. Rank held Boston Scientific as of Q1 2026.
Based on Lazard Asset Management's 13F filing for Q1 2026, filed 15 May 2026.